Laura Pazzaglia
Overview
Explore the profile of Laura Pazzaglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Scotto di Carlo F, Pazzaglia L, Mumm S, Benassi M, De Chiara A, Franchi A, et al.
J Bone Miner Res
. 2020 Feb;
35(10):1974-1980.
PMID: 32106343
Neoplastic transformation is a rare but serious complication of Paget's disease of bone (PDB), occurring in fewer than 1% of individuals with polyostotic disease. Their prognosis is poor, with less...
12.
Scotto di Carlo F, Pazzaglia L, Esposito T, Gianfrancesco F
J Bone Miner Res
. 2020 Jan;
35(8):1387-1398.
PMID: 31991009
Paget's disease of bone (PDB) is a late-onset disorder frequently caused by mutations in the SQSTM1 gene, leading to hyperactive osteoclasts and resulting in bone pain, deformities, and fractures. However,...
13.
Bianchi G, Sambri A, Pedrini E, Pazzaglia L, Sangiorgi L, Ruengwanichayakun P, et al.
Virchows Arch
. 2019 Aug;
476(3):445-454.
PMID: 31463729
Solitary fibrous tumor is a rare mesenchymal neoplasm that exhibits a broad spectrum of biological behaviors. Few studies relative to clinical-pathologic features and predictive factors have been reported, all involving...
14.
Alleva R, Tognu A, Tomasetti M, Benassi M, Pazzaglia L, van Oven H, et al.
PLoS One
. 2019 Jul;
14(7):e0219113.
PMID: 31344051
Objectives: To investigate the modulation of genes whose expression level is indicative of stress and toxicity following exposure to three anaesthesia techniques, general anaesthesia (GA), regional anaesthesia (RA), or integrated...
15.
Pollino S, Palmerini E, Dozza B, Bientinesi E, Piccinni-Leopardi M, Lucarelli E, et al.
J Bone Oncol
. 2019 Jun;
17:100239.
PMID: 31193811
Osteosarcoma (OS) is the most frequent primary malignant tumour of bone and metastases occur in 30% of cases, the 5-year survival rate is 25-30%. Although pre- and post-operative chemotherapy has...
16.
Pazzaglia L, Pollino S, Vitale M, Bientinesi E, Benini S, Ferrari C, et al.
Int J Oncol
. 2018 Nov;
54(1):361-369.
PMID: 30431073
Synovial sarcoma (SS) is a rare tumour, with dismal survival when metastasis occurs. SS contains a characteristic translocation (X;18)(p11;q11) and the fusion genes appear to be mutually exclusive and concordant...
17.
Conti A, Luchini A, Benassi M, Magagnoli G, Pierini M, Piccinni-Leopardi M, et al.
Proteomics Clin Appl
. 2018 Jul;
12(6):e1800041.
PMID: 30054970
Purpose: Approximately 5% of giant cell tumors (GCT) of bone develop pulmonary metastases. Although many biomarkers have been proposed, identification of circulating low abundance molecules may be useful to predict...
18.
Pollino S, Benassi M, Pazzaglia L, Conti A, Bertani N, Righi A, et al.
Histol Histopathol
. 2018 Jan;
33(6):597-608.
PMID: 29297565
Background: The outcome of patients with metastatic soft tissue sarcoma (STS) remains unfavourable and new therapeutic strategies are needed. The aim of this study was to determine the role of...
19.
Divisato G, Scotto di Carlo F, Pazzaglia L, Rizzo R, Coviello D, Benassi M, et al.
Oncotarget
. 2017 Oct;
8(38):63121-63131.
PMID: 28968976
Giant Cell Tumor of Bone (GCT) is a tumor characterized by neoplastic mesenchymal stromal cells and a high number of osteoclast-like multinucleated giant cells. Rarely, GCT could arise in bones...
20.
Pazzaglia L, Novello C, Conti A, Pollino S, Picci P, Benassi M
Cell Oncol (Dordr)
. 2016 Dec;
40(1):77-88.
PMID: 27900663
Purpose: Highly aggressive adult soft tissue sarcomas (STS), i.e., leiomyosarcomas (LMS) and undifferentiated pleomorphic sarcomas (UPS), present complex genomic anomalies and overall 5-year survival rates of 20 to 40%. Here,...